Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Minerva Chir ; 57(2): 197-202, 2002 Apr.
Artigo em Italiano | MEDLINE | ID: mdl-11941294

RESUMO

Carcinoma of the main biliary way is a condition that often leads to a fatal outcome owing to the rapid growth and late onset of the symptoms. The importance of a correct, timely diagnosis is stressed, with reference to a clinical case in which even CT scanning did not confirm either the presence of the neoformation or the dilation of the intra and extrahepatic bile ways. The usefulness of humoral markers for the diagnosis of the disease in its preclinical phase in the interests of surgical treatment that is as radical as possible is underlined.


Assuntos
Adenocarcinoma Papilar/cirurgia , Neoplasias dos Ductos Biliares/cirurgia , Adenocarcinoma Papilar/diagnóstico , Adenocarcinoma Papilar/etiologia , Idoso , Neoplasias dos Ductos Biliares/diagnóstico , Neoplasias dos Ductos Biliares/etiologia , Humanos , Masculino
2.
Int J Clin Pharmacol Ther ; 38(8): 402-7, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10984014

RESUMO

INTRODUCTION: Erdosteine is an original drug which has been suggested as secretolytic compound and promoter of respiratory ventilation in the treatment of acute and chronic respiratory diseases. Moreover, the drug possesses also scavenging, antioxidant, and bacterial anti-adhesivity properties. From a clinical point of view the best results have been obtained by combined treatment with an antibiotic agent of useful spectrum activity. Aim of the present study was to evaluate the improvement induced in the risk/benefit ratio by erdosteine on the broad-spectrum antibiotic (ampicillin) in the treatment of acute lower respiratory tract diseases in the pediatric field. MATERIAL AND METHODS: A controlled multicenter double-blind parallel group trial was planned comparing erdosteine, supplied as syrup 3.5% or as sachets 225 mg, versus the relevant placebo. The tested compounds were administered in association with ampicillin. Two-hundred (n = 200) subjects entered the trial, randomly selected among patients monitored by the different centers, and were assigned to one of the treatments under evaluation, i.e. active compound or placebo with the aim to constitute two comparative homogeneous groups of 100 subjects each. Subsequently each group was again divided according to age in two equivalent subgroups of 50 patients each and treated with the syrup 3.5% (age from 2 to 4 years) or the sachet form (age from 5 to 10 years). The treatments administered in the two comparison groups were erdosteine (syrup 3.5% and 225 mg sachets) or the relevant placebo. The erdosteine posologies were adapted according to age. The lower dosage of the 5-10 years range in comparison with the 2-4 years range was established on the base of bioavailability characteristics of the two pharmaceutical forms. In all groups ampicillin was administered at the dosage of 100 mg/kg/day, according to a b.i.d. time schedule. The primary efficacy criterion was the cough score evaluated in a subjective way and expressed with the following scores: 1 = absent; 2 = mild; 3 = moderate; 4 = severe. The secondary efficacy end-points were: body temperature (expressed in degrees C); the polypnea, ronchi and rales estimation with a rating scale similar to that previously mentioned. These parameters were determined before starting of the treatment (VO); at the 3rd +/- 1 (V1) and at the 7th +/- 2 (V2) day of treatment. The body temperature was measured orally in the morning at awakening time with a mercury thermometer. Obtained data expressed in Celsius degrees are recorded by the investigator in the patient file during control visits. The safety of adopted treatments was evaluated with two different approaches. The clinical part was determined with the adverse drug reactions (ADRs) estimate. The biological safety was estimated at admission day (day 0) and at the final visit by means of a sophisticated statistical approach. RESULTS: The final results were the following: Erdosteine syrup 3.5%: concerning cough (primary end-point) in the group of patients (n = 50) treated with erdosteine it has been possible to point out a reduction of 23.8% at V1, i.e. after 3+/-1 days, and of 59.8% at V2, i.e. after 7+/-2 days. In the group of patients treated with placebo (n = 50) the reduction has been of 20.1% at V1 and of 36.6% at V2. The statistical analysis evidenced p values < 0.01 for times, treatments, time x treatments. The relevant results are summarized in Table 2. Erdosteine sachets 225 mg: concerning cough (primary end-point) in the group of patients (n = 50) treated with erdosteine it has been possible to point out a reduction of 17.6% at V1, i.e. after 3+/-1 days, and of 56.8% at V2, i.e. after 7+/-2 days. In the group of patients treated with placebo (n = 50) the reduction has been of 15.6% at V1 and of 31.8% at V2. The statistical analysis evidenced p values < 0.01 for times, treatments, time x treatments. (ABSTRACT TRUNCATED)


Assuntos
Expectorantes/uso terapêutico , Doenças Respiratórias/tratamento farmacológico , Tioglicolatos/uso terapêutico , Tiofenos/uso terapêutico , Administração Oral , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Pré-Escolar , Método Duplo-Cego , Quimioterapia Combinada , Expectorantes/administração & dosagem , Expectorantes/efeitos adversos , Feminino , Febre/tratamento farmacológico , Humanos , Lactente , Masculino , Tioglicolatos/administração & dosagem , Tioglicolatos/efeitos adversos , Tiofenos/administração & dosagem , Tiofenos/efeitos adversos , Resultado do Tratamento
3.
Minerva Chir ; 55(1-2): 59-63, 2000.
Artigo em Italiano | MEDLINE | ID: mdl-10832286

RESUMO

The Peutz-Jeghers syndrome is considered a familial polyposis syndrome. The polyps are of hamartomatous type. The symptomatology is due to the more voluminous polyps which can necrotize, ulcerate, bleed and cause intussusception and intestinal obstruction. A case of ileum-ileal intussusception due to Peutz-Jeghers syndrome is reported. The utility of a genealogic research is underlined and the recent results of the genetic research are evaluated. The surgical therapy of Peutz-Jeghers syndrome can have many aims: 1) to remove all big polyps, 2) to avoid the danger of canceration, 3) to prevent the hemorrhagic or occlusive risks and complications.


Assuntos
Doenças do Íleo/etiologia , Intussuscepção/etiologia , Síndrome de Peutz-Jeghers/complicações , Adulto , Feminino , Seguimentos , Humanos , Doenças do Íleo/cirurgia , Intussuscepção/cirurgia , Masculino , Linhagem , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/cirurgia , Fatores de Tempo
4.
Minerva Chir ; 54(4): 257-60, 1999 Apr.
Artigo em Italiano | MEDLINE | ID: mdl-10380525

RESUMO

The best therapeutic treatments for early gastric cancer are evaluated. Due to the difficulty of preoperative and intraoperative staging, it's reasonable to consider early gastric cancer as a composite disease; while some mucous localizations can benefit of minor therapeutic treatments, the submucous cancer must be treated as the parietal gastric cancer.


Assuntos
Neoplasias Gástricas/cirurgia , Ensaios Clínicos como Assunto , Humanos , Metástase Linfática , Estudos Prospectivos , Estudos Retrospectivos , Fatores de Tempo
5.
Minerva Chir ; 52(12): 1425-34, 1997 Dec.
Artigo em Italiano | MEDLINE | ID: mdl-9557455

RESUMO

Having re-examined the nosographic data acquired on the subject of hepatic polycystosis and uterine adnexal cysts, the authors report the results of their experience. On the basis of the evaluation of these results (no laparotomic conversion, no postoperative complications, reduced hospital stay), which are comparable to those reported in the literature, the authors conclude that the modern technology may be used to advantage in all cases where laparoscopic surgery is not difficult, does not require numerous tests and does not entail a high risk of complications.


Assuntos
Doenças dos Anexos/cirurgia , Cistos/cirurgia , Laparoscopia/métodos , Hepatopatias/cirurgia , Doenças dos Anexos/diagnóstico , Cistos/diagnóstico , Feminino , Humanos , Hepatopatias/diagnóstico , Pessoa de Meia-Idade , Cistos Ovarianos/diagnóstico , Cistos Ovarianos/cirurgia , Resultado do Tratamento
6.
Minerva Chir ; 52(12): 1495-502, 1997 Dec.
Artigo em Italiano | MEDLINE | ID: mdl-9557464

RESUMO

The authors underline the role of inheritance in colorectal cancer and reporting the genealogical study of two families with high incidence of colorectal cancers personally observed. They thought that the genetic endowment (oncogenes, suppressor genes, microsatellite instability, protein-kinase C) was implicated directly in the genesis of disease.


Assuntos
Adenocarcinoma/genética , Neoplasias Colorretais/genética , Adenocarcinoma/cirurgia , Polipose Adenomatosa do Colo/genética , Adulto , Neoplasias Colorretais/cirurgia , Genes Supressores de Tumor/genética , Humanos , Masculino , Oncogenes/genética , Linhagem , Proteína Quinase C/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA